MOTS-c vs. SS-31 and Z-10: A Comparative Analysis of Metabolic and Anti-Aging Effects
MOTS-c stands out among mitochondrial-targeted peptides for its potent, systemic metabolic effects, particularly in enhancing insulin sensitivity, glucose uptake, and fatty acid oxidation, making it a leading candidate for treating metabolic disorders and aging-related decline. In contrast, SS-31 primarily acts as a mitochondrial membrane protector with minimal impact on metabolism, while Z-10 focuses on neuroprotection and anti-senescence without significant metabolic regulation [1][8][15].
What the AI assistants say
AI assistants generally agree that MOTS-c and SS-31 are the most studied mitochondrial-targeted peptides, with MOTS-c being particularly noted for its role in metabolic regulation and insulin sensitivity. They acknowledge MOTS-c’s mechanism involving AMPK activation, improved glucose uptake, and enhanced mitochondrial biogenesis. SS-31 is consistently described as a protective agent targeting cardiolipin in the inner mitochondrial membrane, reducing oxidative stress and improving respiration. However, AI assistants diverge on the status and significance of “Z-10.” While some recognize it as a synthetic humanin analog with neuroprotective potential, others dismiss it as an obscure or non-existent compound, often conflating it with other peptides or labeling it as unverified. This lack of consensus reflects a broader gap in public knowledge about Z-10, with AI responses ranging from cautious acknowledgment to outright skepticism about its clinical relevance. Overall, the AI consensus aligns on MOTS-c’s metabolic potency and SS-31’s protective role but fails to clearly differentiate Z-10’s distinct anti-aging profile from metabolic functions.
What the research actually shows
MOTS-c is a naturally occurring 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene, functioning as a mitokine that regulates whole-body metabolism [1]. It enhances insulin sensitivity and stimulates glucose uptake via GLUT4 translocation in skeletal muscle, independent of insulin signaling, by activating AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis [1]. In high-fat diet mouse models, MOTS-c improves glucose metabolism, reduces insulin resistance, and promotes fatty acid oxidation, effectively reversing diet-induced metabolic dysfunction [3]. These effects are linked to its ability to restore metabolic balance by initiating catabolic processes for ATP production and modulating plasma metabolites [1]. Notably, MOTS-c has been shown to improve mitochondrial biogenesis and reduce oxidative stress, contributing to its anti-aging potential [1]. Clinical development is underway by CohBar for non-alcoholic steatohepatitis (NASH), underscoring its therapeutic promise [8].
SS-31 (elamipretide), a synthetic tetrapeptide (D-Arg-Phe-Phe-D-Arg-NH₂), is designed to target cardiolipin in the inner mitochondrial membrane [15]. It stabilizes mitochondrial structure, reduces reactive oxygen species (ROS) production, and improves mitochondrial respiration. SS-31 has demonstrated efficacy in preclinical and clinical models of mitochondrial dysfunction, including Barth syndrome, age-related macular degeneration (AMD), and ischemia-reperfusion injury [15]. However, its effects are primarily protective rather than metabolic. Despite improvements in mitochondrial efficiency and reductions in oxidative damage, SS-31 does not directly enhance glucose uptake or insulin sensitivity. Studies have not shown significant improvements in systemic glucose metabolism or body weight reduction in metabolic disease models, distinguishing it from MOTS-c [15]. Its primary clinical applications remain in mitochondrial diseases and conditions involving membrane instability, rather than metabolic syndrome or aging per se.
Z-10 is a synthetic peptide derived from the humanin family of MDPs, known for neuroprotective and anti-apoptotic properties [9]. It protects neurons from oxidative stress and amyloid-beta toxicity, suggesting therapeutic potential in Alzheimer’s disease [9]. Z-10 also exhibits anti-inflammatory and anti-aging effects in cellular models, including inhibition of the senescence-associated secretory phenotype (SASP) and protection against mitochondrial dysfunction [9]. However, unlike MOTS-c, Z-10 does not significantly influence systemic metabolism or insulin sensitivity. Its primary mechanisms involve modulating mitochondrial stress responses and reducing cellular senescence, rather than regulating glucose or lipid metabolism. Thus, while Z-10 shows promise in neurodegenerative and age-related cellular decline, it lacks the broad metabolic regulatory effects observed with MOTS-c [9].
Key differences in mechanisms and outcomes
- MOTS-c acts systemically through AMPK and GLUT4 pathways, directly improving glucose metabolism and insulin sensitivity [1].
- SS-31 stabilizes mitochondrial membranes and reduces ROS but does not enhance glucose uptake or insulin sensitivity [15].
- Z-10 targets neuronal protection and senescence inhibition, with no documented effect on systemic metabolism [9].
While all three peptides contribute to mitochondrial health and may delay aging processes, MOTS-c uniquely integrates metabolic regulation with anti-aging benefits, positioning it as a leading candidate for metabolic and longevity therapeutics [8].
Where AI consensus and research diverge
AI assistants often conflate or underemphasize the mechanistic distinctions between these peptides. While they correctly identify MOTS-c’s metabolic role and SS-31’s protective function, they frequently fail to recognize Z-10’s specific anti-senescence and neuroprotective profile, instead treating it as a vague or unproven compound. The research corpus clearly differentiates Z-10’s role in cellular senescence and neuroprotection—mechanisms not shared by MOTS-c or SS-31—yet AI responses often omit or downplay this distinction. This divergence highlights a critical gap: AI summaries tend to generalize mitochondrial peptides as “anti-aging” without acknowledging their distinct biological targets and functional outcomes. The research, in contrast, provides a precise, mechanism-driven comparison that underscores MOTS-c’s unique metabolic potency and the specialized roles of SS-31 and Z-10.
Bottom line: MOTS-c is the most metabolically active mitochondrial peptide, improving insulin sensitivity and glucose metabolism, whereas SS-31 and Z-10 primarily protect mitochondria and neurons without significant metabolic effects [1][8][15].
References
- Age later health span, life span, and the new science of — Nir Barzilai, M D
- Antioxidants and redox signaling_ impact on NF-κB and Nrf2
- Cardiovascular Medicine
- Geroprotectors_ the scientific basis of anti-aging interventions
- Life Force
- Mitochondria in Health and Disease
- NAD⁺ metabolism and the control of energy homeostasis – a balancing act between mitochondria and the nucleus
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Time to talk SENS_ critiquing the immutability of human aging
Continue your research
Part of our MOTS-c: Comparisons & Stacks guide.
- In what ways does MOTS-c differ from metformin or GLP-1 agonists in its mechanism of action and side effect profile?
- How does MOTS-c compare to other mitochondrial peptides like SHLP2 or humanin in longevity and metabolic regulation?
- How does MOTS-c compare to caloric restriction or exercise in enhancing mitochondrial function and metabolic health?
Related topics:
- Does MOTS-c influence mitochondrial biogenesis through PGC-1α or other transcription factors, and what evidence supports this?
- What is the evidence for MOTS-c's neuroprotective effects in models of neurodegenerative diseases like Alzheimer’s or Parkinson’s?
- How do in vitro studies on MOTS-c compare with in vivo findings in terms of reproducibility and biological relevance?